🇺🇸 FDA
Patent

US 11897874

Compounds and methods for modulating Interleukin-2-inducible T-cell kinase

granted A61PA61P35/00A61P43/00

Quick answer

US patent 11897874 (Compounds and methods for modulating Interleukin-2-inducible T-cell kinase) held by Corvus Pharmaceuticals, Inc. expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Corvus Pharmaceuticals, Inc.
Grant date
Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
29
CPC classes
A61P, A61P35/00, A61P43/00